文献速递肺外科

非小细胞肺癌手术患者血浆与组织DNA突变比较

Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-05-24

该前瞻性研究纳入76例接受根治性肺切除的疑似肺癌患者,采用靶向二代测序检测肿瘤组织DNA与血浆循环肿瘤DNA的体细胞突变。ctDNA与tDNA总体一致率为68.4%,术前与术中ctDNA突变频率差异小(1.2%),术后降至平均0.28%(P < .001)。ctDNA阳性患者(48例,63.2%)多于血清肿瘤蛋白标志物阳性者(36例,49.3%),且ctDNA评估孤立性肺结节恶性的曲线下面积(0.887,95%CI 0.788-0.986)高于两个预测模型。

要点

  • I-III期NSCLC手术患者ctDNA突变分析可行,与组织DNA一致率68.4%。
  • 术后ctDNA突变频率平均降至0.28%,较术前术中显著降低(P < .001)。
  • ctDNA评估孤立性肺结节恶性的AUC为0.887,优于两个预测模型。

核心结论

  • I-III期NSCLC手术患者进行ctDNA突变分析是可行的,但临床应用仍需更多研究。

研究设计与样本

  • 前瞻性纳入连续接受根治性肺切除的疑似肺癌患者76例,对配对肿瘤组织DNA和血浆ctDNA进行靶向二代测序,血浆采集于术前、术中及术后。

主要发现

  • 76例肺癌患者中,31例ctDNA与tDNA检出相同突变,21例两者均无突变,总体一致率68.4%。
  • 术前与术中ctDNA突变频率差异小(1.2%),术后平均降至0.28%(P < .001)。
  • ctDNA阳性患者48例(63.2%),血清肿瘤蛋白标志物阳性36例(49.3%)。
  • ctDNA评估孤立性肺结节恶性的AUC为0.887(95%CI 0.788-0.986),两个预测模型分别为0.803(95%CI 0.647-0.959)和0.69(95%CI 0.512-0.869)。

临床怎么用

  • 对于I-III期NSCLC手术患者,可考虑围手术期ctDNA检测辅助评估肿瘤突变负荷及术后微小残留病灶。
  • ctDNA对孤立性肺结节恶性评估的AUC较高,可作为无创辅助诊断工具,但需结合影像和病理。

局限性

  • 研究样本量较小(76例),且仅纳入手术患者,结论外推需谨慎。
  • 原文未报告检测限、随访时间及预后关联等数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Noninvasive liquid biopsies of circulating tumor DNA (ctDNA) can be used to assess non-small cell lung cancer (NSCLC), but previous work focused on patients with advanced-stage cancer. Thus, we evaluated the feasibility and their potential clinical application of circulating tumor DNA approached for surgical patients with NSCLC. METHOD: Consecutive patients with suspected lung cancer who underwent curative-intent lung resection were enrolled prospectively in this study. Targeted DNA sequencing with a next-generation sequencing platform was used to identify a series of somatic mutations in matched tumor tissue DNA (tDNA) and plasma ctDNA samples. Plasma was collected before, during, and after surgery. Concordance was defined as matched tDNA and ctDNA with the same identified mutations or with no mutations. RESULTS: In the enrolled 76 patients with lung cancer who were included, 31 had concordant mutations and 21 had no mutation in both ctDNA and tDNA, yielding an overall concordance of 68.4%. ctDNA samples obtained before and during surgery had the same mutations with a low variance in mutation frequency (1.2%) that was reduced to an average of 0.28% after surgery (P < .001). More patients were positive as assayed by ctDNA (48; 63.2%) than with serum tumor protein markers (36; 49.3%). The area under the curve was greater in ctDNA (0.887, 95% confidence interval [CI], 0.788-0.986) than for the 2 prediction models (0.803, 95% CI, 0.647-0.959; 0.69, 95% CI, 0.512-0.869) for estimating malignancy of solitary pulmonary nodules. CONCLUSION: ctDNA mutation analysis for stage I-III surgical patients with NSCLC is feasible. More studies are needed to investigate its clinical application.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Chen K, Zhang J, Guan T, et al. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2017. PMID: 28625771. doi:10.1016/j.jtcvs.2017.04.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。